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Approximately 1.2 million people within the United 
States are currently living with human 
immunodeficiency virus (HIV) infections, and, in Georgia 
50,436, people were living with diagnosed HIV as of 
December 31, 2012 (The Georgia Department of Public 
Health Fact Sheet: HIV Surveillance, Georgia, 2012). Due 
to the advancement of antiretroviral therapy, people 
living with HIV (PLWH) are living longer. As PLWH age, 
they face the same chronic illnesses as the general 
population, including cardiovascular disease and chronic 
obstructive pulmonary disease (Moscou-Jackson, 
Commodore-Mensah, Farley, & DiGiacomo, 2014).  
 
Smoking prevalence among PLWH is higher than that of the 
general population. An estimated 21.2% of adults in the 
United States smoke cigarettes (CDC, 2013; Browning, 
Wewers, Ferketich, & Diaz, 2013), but a study of a 
nationally representative sample of HIV-infected persons in 
care found adults with HIV were nearly twice as likely to 
smoke compared to adults in the general population (42.4% 
and 20.6%, respectively) and were less likely to quit 
compared to the general population (quit ratios: 32.4% vs. 
51.7%, respectively) (Mdodo et al., 2015). Tobacco use is 
high among PLWH due to several underlying factors. Both 
tobacco use and HIV are associated with lower educational 
achievement, lower income level, concurrent drug use, and 
mental illness (O’Cleirigh et al., 2015). Tobacco use 
presents an increased risk of both AIDS-defining and other 
diseases for HIV-infected smokers, compounding the effect 
of high rates of smoking in this population (Helleberg et al., 
2013). 
 
The purpose of this study was to compare the prevalence of 
smoking among PLWH in Georgia to that for the general 
population in Georgia, using data from the Georgia Medical 
Monitoring Project (MMP), a representative sample of 
persons in HIV care in Georgia, and data from the Georgia 
Behavioral Risk Factor Surveillance System (BRFSS). 
Understanding the prevalence and harmful effects of 
tobacco use among Georgians living with HIV will inform 
tobacco cessation programs specific to Georgia as well as 
educate HIV care providers in Georgia. 
 
RESEARCH AND PRACTICE 
ABSTRACT 
Background: Since the advent of highly active antiretroviral therapy in the mid-nineties, deaths among persons living with 
HIV (PLWH) have declined nationally. Now a controllable condition, HIV has become a chronic disease, highlighting the 
importance of tobacco cessation in lowering morbidity and premature mortality. Current smoking is approximately twice as 
high among PLWH compared with the general population. PLWH who smoke experience higher rates of cardiovascular 
disease, AIDS-defining illnesses, and cancer than PLWH who do not smoke. Loss of life-years associated with smoking 
among PLWH is greater than life-years lost from HIV.  
 
Methods: Data on current smoking, derived from the 2009-12 Georgia Medical Monitoring Project (MMP) were analyzed. 
Smoking rates were calculated by demographic characteristics, and results were compared to those from the 2011 Georgia 
Behavioral Risk Factor Surveillance System (BRFSS), a population-based telephone survey.  
 
Results: The prevalence of current smoking among PLWH was 36.1%, compared with 21.2% among the general population 
in Georgia. Smoking prevalence for PLWH generally varied by demographic characteristics according to the same pattern as 
for the general population, but prevalence was consistently higher among PLWH. 
 
Conclusions: The prevalence of current smoking among PLWH in Georgia is high. Clinical and public health interventions 
must address smoking cessation as part of HIV care to prevent disease, improve quality of life, and reduce mortality. HIV-
infected smokers have more barriers to quitting (alcohol, depression, drug dependence, and inaccurate risk perception) and a 
lower quit rate than non-HIV-infected smokers. Efficacy studies of behavioral and pharmacological interventions for smoking 
cessation specific to PLWH are needed. 
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METHODS 
 
The Georgia MMP data from 2009-2012 were analyzed to 
estimate smoking prevalence by sociodemographic variables 
among smokers. MMP is a surveillance system that collects 
data about behavioral and clinical aspects of PLWH who are 
currently receiving medical care (“Georgia Medical 
Monitoring Project (MMP) | Georgia Department of Public 
Health”). MMP utilizes a three-stage, probability sampling 
method, and Georgia is one of 26 states and cities across the 
United States that participates. Within project areas, 
facilities and patients within those facilities are randomly 
selected. Interviews are conducted either face-to-face or via 
telephone to obtain behavioral information, and medical 
records are used to obtain clinical information. To be 
eligible to participate, individuals are required to be HIV-
infected, 18 years of age or older at the time of the 
interview, and actively receiving medical care for HIV. Data 
from the Georgia MMP are weighted to produce a 
representative sample of all adult Georgians receiving 
medical care for HIV (McNaghten et al., 2007; Blair et al., 
2011; Frankel et al., 2012). Because results varied 
minimally during 2009-2012, data from the four survey 
years were pooled to achieve a larger sample size. 
The Georgia Behavioral Risk Factor Surveillance System 
(BRFSS) data from 2011 were analyzed to estimate 
smoking prevalence among the general population of 
Georgia adults by sociodemographic variables. BRFSS 
collects information regarding health risk behaviors, health 
conditions, and use of healthcare services. Data are 
collected in all 50 states, and the surveys are completed via 
telephone interviews. Beginning in 2011, BRFSS collected 
data from both landline telephones, using a disproportionate 
stratified sampling method, and cellular telephones, using a 
random, probability sampling method. BRFSS data, like 
MMP data, are weighted to produce nationally 
representative samples as well as representative samples for 
each state (“CDC - BRFSS,”). Analyses were conducted 




Smoking prevalence among PLWH in Georgia was almost 
twice as high as smoking prevalence among the general 
population (36.1% vs. 21.2%). For PLWH, current smoking 
was more common among females than males, whites than 
blacks, persons with a high school education or less, and 
persons 25 years and older. With the exception of 
differences by sex, similar patterns were seen in the general 
population. Within each subgroup, current smoking was 
higher among PLWH (Table 1). 
 
 
Table 1. Prevalence of Current Smoking by Demographics, PLWH (MMP 2009-2012) 
           and all Adults (BRFSS 2011) in Georgia 
  PLWH All Adults 
Georgia MMP 2009-2012 Georgia BRFSS 2011 






Overall 607 36 1,612 21 
Sex         
  Female 172 39 942 18 
  Male 429 35 670 23 
Race/Ethnicity         
  White 138 41 1,159 24 
  Black 407 34 331 17 
  Hispanic 26 -* 46 13 
Education         
  <High school 95 55 292 36 
   H.S. graduate 172 43 562 24 
  >High school 340 27 752 15 
Age in years         
   18-24 29 -* 84 25 
   25-44 261 40 425 24 
   45-64 290 36 780 22 
   65+ 26 -* 288 13 
Income         
 Less than $20K 137 40 492 33 
 $20K or more 103 24 919 17 
*unreliable estimate 
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DISCUSSION 
 
In the United States, tobacco use is the leading cause of 
preventable illness and death, and after viral suppression, 
tobacco cessation remains the number one health priority for 
PLWH who smoke. In Georgia, rates of current smoking are 
almost twice as high among PLWH than among the general 
population. The findings are consistent with those of other 
studies on smoking prevalence among PLWH.  
 
PLWH who smoke have a substantially increased risk of 
cardiovascular disease; AIDS-defining conditions, including 
candidiasis, bacterial pneumonia, cervical cancer, and anal 
cancer; lung cancer; and liver cancer (Helleberg et al., 2013; 
Kwong & Bouchard-Miller, 2010; Lifson 2010). Smoking 
causes a systemic inflammation and decreases immune 
function, which contributes to the increased risk of diseases 
and certain types of cancers (Helleberg et al., 2013) . 
Compared to smokers in the general population, HIV-
infected smokers are more susceptible to developing chronic 
obstructive pulmonary disorder (Crothers et al., 2006). 
Premature mortality is also substantially increased in PLWH 
who smoke compared to those who do not smoke (Figure 1) 
(Helleberg et al., 2013). Life expectancy for a 35-year-old 
HIV patient who smokes is 62.6 years, compared with 78.4 
years for a non-smoking patient with HIV. Both all-cause 
and AIDS mortality are higher among PLWH who smoke, 
including a nearly five-fold increased risk of death caused 
by cardiovascular disease and cancer compared to HIV-
infected non-smokers (Helleberg et al, 2013). The 
attributable risk of death associated with smoking is 61.5% 
among PLWH compared to 34.2% among HIV-negative 
controls.  
 
Cigarette smoking is associated with lower adherence to 
antiretroviral therapy (ART) (Shuter & Bernstein, 2008), 
and smoking is also associated with a greater risk of 
virologic failure (Feldman et al., 2006). Even after 
controlling for adherence, cigarette smoking was associated 
with a decrease in the efficacy of ART, suggesting that an 
underlying biological mechanism exists between smoking 
and ART (O’Cleirigh et al., 2015). 
 
Due to the high prevalence of smoking among PLWH and 
the increased risk of disease and premature mortality among 
HIV-infected smokers, tobacco cessation should be a goal 
for HIV care providers. However, there are many barriers to 
quitting. Inaccurate risk perceptions, depression and mental 
illness, and concurrent alcohol and drug use all negatively 
impact tobacco cessation efforts (O’Cleirigh et al., 2015). 
Cessation counseling programs for patients who are 
codependent on other substances (e.g., alcohol and 
marijuana) are more successful when both substance abuse 
cessation and tobacco cessation are included than when 
either cessation program is implemented alone (Helleberg 
et al., 2013).  
 
Recent molecular biology research demonstrates that 
nicotine causes structural changes in ΔFosB receptors in the 
mouse brain striatum, which is a factor in the development 
of addiction behavior (Rosenberg, 2014; Kandel & Kandel, 
2014). Priming mice with nicotine also enhances the effect 
of cocaine. This priming effect has implications for harm 
reduction approaches, such as the use of e-cigarettes (Levine 
et al., 2005). Since e-cigarettes are nicotine-delivery 
devices, they do not provide an optimal strategy for harm 
reduction for populations with high substance abuse 
prevalence due to the effect of nicotine on enhancement of 
the effects of other drugs. By such enhancement, e-
cigarettes pose the same risks as traditional cigarettes and 
present additional barriers to cessation of tobacco and 
substance use (Kandel & Kandel, 2014). 
 
In the general population, only 20.9% of smokers receive 
tobacco cessation counseling, and only 7.6% receive 
tobacco cessation medication (Jamal et al., 2012). Some 
studies have demonstrated that providers of healthcare to 
PLWH are more likely to discuss tobacco cessation 
strategies with their patients than primary care providers; 
however, only half of all such providers report screening 
and counseling for tobacco use (Benard et al., 
2007;Tesoriero, Gieryic, Carrascal, & Lavigne, 2010). 
Shuter et al. examined smoking behaviors among PLWH 
and found and 83% of participants reported their primary 
care provider initiated discussions regarding smoking. 
However, only 32.8% were referred to a quit line, and only 
5.3% were referred to a smoking cessation program (Shuter, 
Bernstein, & Moadel, 2012). Reasons for lack of adequate 
counseling by those providing care to PLWH were that 
tobacco cessation counseling involved time limitations 




PLWH who are not receiving care or not receiving 
consistent care were not included in this sample. Individuals 
receiving care may be more health conscious and less likely 
to smoke than individuals who are not receiving care; 
therefore, smoking prevalence among Georgians living with 
HIV may be underestimated. The response rates for the 
Georgia MMP were 27.39% for 2009, 17.58% for 2010, 
23.23% for 2011, and 34.71% for 2012. The adjusted 
response rate for Georgia BRFSS was 49.92% for 2011. 
Lower response rates could lead to nonresponse bias and 
affect the generalizability of results.  
 
Implications for Public Health 
Findings of high smoking prevalence among PLWH 
combined with the increased risk of diseases and mortality 
for PLWH smokers highlight the importance of tobacco 
cessation among this population. These results should 
inform tobacco cessation programs tailored to people living 
with HIV in Georgia. A recent review assessed tobacco 
cessation programs among HIV-positive persons (Moscou-
Jackson et al., 2014). Interventions that incorporated cell 
phone cessation strategies were the most successful at 
increasing smoking cessation rates (Vidrine, Arduino, 
Lazev, & Gritz, 2006; Vidrine, Marks, Arduino, & Gritz, 
2012). The review concluded that the most successful 
interventions were adjusted to address specific needs of 
PLWH (Moscou-Jackson et al., 2014). Also, interventions 
that addressed co-occurring substance abuse and psychiatric 
disorders were more successful at achieving tobacco 
cessation than interventions that did not address these 
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comorbidities (Moscou-Jackson et al., 2014). Combinations 
of different cessation strategies, including pharmacotherapy, 
education, and counseling, would be more beneficial to this 
population (Moscou-Jackson et al., 2014). 
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